

## Review on Defensive Roles of Thymoquinone Nanobiosensing Prospective in Opposition to Cancer

Dr. A. Mohamed Sikkander<sup>1</sup>, Dr. Khadeeja Yasmeen<sup>2</sup>

<sup>1</sup>(Department of Chemistry, Velammal Engineering College, Chennai-INDIA)

<sup>2</sup>(Department of Biotechnology, North East Frontier Technical University, Arunachal Pradesh)

<sup>1</sup>Corresponding Author: [ams240868@gmail.com](mailto:ams240868@gmail.com)

### To Cite this Article

Dr. A. Mohamed Sikkander, Dr. Khadeeja Yasmeen, "Review on Defensive Roles of Thymoquinone Nanobiosensing Prospective in Opposition to Cancer", *Journal of Science and Technology*, Vol. 06, Issue 02, March-April 2021, pp58-63

### Article Info

Received: 14-11-2020

Revised: 22-01-2021

Accepted: 27-01-2021

Published: 03-02-2021

**Abstract:** Thymoquinone (TQ), the most important bioactive constituent of *Nigella sativa*, has been originating to exhibit anticancer effects in plentiful preclinical studies. Due to its multi targeting character, TQ interferes in an extensive assortment of tumorigenic processes and counteracts carcinogenesis, malicious growth, incursion, exodus, and angiogenesis. Moreover, TQ can exclusively sensitize tumor cells on the way to predictable cancer treatments (e.g., chemotherapy, immunotherapy, and radiotherapy) and at the same time lessen psychoanalysis connected lethal effects in regular cells. In this review, we summarized the adjuvant prospective of TQ as observed in an assortment of in vitro and in vivo animal models and discussed the pharmacological properties of TQ to diminish its additional role in potentiating the usefulness of usual remedial modalities specifically surgery, radiotherapy, chemotherapy, and immunotherapy. On the whole we suggest supplementary ample evaluation of TQ in preclinical and clinical levels to demarcate its obscure usefulness as a novel corresponding adjuvant remedy for cancer treatment.

The focal point on nanotechnology for enhanced bioavailability and drug deliverance is of increasing significance for organizing different human diseases. Therefore, copious nanoformulations have been urbanized for the oral bioavailability of different drugs. This appraisal introduces applications of nanomedicine to improve the biological actions of thymoquinone (TQ) to be in charge of dissimilar diseases in more than a few in vivo studies as a beginning analysis for human disease healing with nano-TQ. Nano-TQ successfully augments the anticancer roles of doxorubicin by up principle of P53 and downward guideline of Bcl2 and potentiates paclitaxel's apoptosis in MCF-7 breast cancer cells. In addition nano-TQ protects in opposition to diabetes, inflammation, CNS, and hepatotoxicity, essentially by enhancement of organs' antioxidant condition. We sum up the pros and cons of several FDA approved nanoparticle-based therapeutics and talk about the roadblocks in clinical translation, along with probable nano-TQ strategies to conquer these roadblocks. From this assessment we can bring to a close that nano-TQ may be measured as a talented nutraceutical for human being healthiness.

**Keywords:** Nanonutraceuticals, Thymoquinone; Plasma Proteins ; Bioavailability ; Anticarcinogenic

### I. Introduction

Botanical and normal drugs have an extensive, recognized history in treating several diseases. *Nigella sativa* grows inside the Mediterranean and within Western Asian areas. *N. sativa* is one of the majority well-known herbs used in Islamic long-established medication. The *N. sativa* seeds have a lot of pharmacological properties for instance antioxidant, anticarcinogenic, antihypertensive, and antidiabetic [1–3] (Figure 1). Thymoquinone (TQ) is the major component of *N. sativa* and has influential anticancer, antioxidant, antimicrobial, antihistaminic, immunomodulatory, and anti-inflammatory natal properties [4,5]. TQ has extensive nutraceutical potential that includes anticancer uses, anti-inflammatory, and antioxidant, but it's far above the ground insecurity [6], speedy abolition, and more than 99% necessary to plasma proteins [7] restrictions the clinical result of TQ treatment [8]. More than a few well-designed, comprehensive reviews casing on top of aspects have been presented [8–12].




Figure no 1: Biological activities of thymoquinone.

Nanonutraceuticals have talented properties that help to conquer the boundaries of a medicine that has a tapered therapeutic window or small bioavailability (Figure 2). Nanonutraceuticals make available defense and diminish renal clearance for a long-drawn-out TQ pharmacological consequence. As an perfect nanonutraceutical, TQ would be delivered to the target tissue or organ, where gratis TQ could then reach a therapeutic attentiveness and be maintained for a required time. Nanomaterials can effortlessly penetrate the biological membranes and make available sustained let loose of TQ to dissimilar body parts [13], and for that reason nanoformulated TQ would augment its bioavailability. Augmentation of drug and food constituents' deliverance and therapeutic special effects have been achieved by a wide hodgepodge of bottom-up encapsulation methods, such as on its own emulsions, dual emulsions, nanoprecipitation, or the ionic gelation technique [14], biopolymer side chains conjugations [15], and top-down methods such as the cold wet-milling method [16]. In addition, nanoparticles (NPs) have been comprehensively used for drug deliverance augmentation such as carbon, ceramic, and chitosan NPs [17].





Figure no. 2: Advantages of thymoquinone nanoformulations

## II. Glio-Blastoma Multiforme (GBM)


Glioblastoma multiforme (GBM) is one of the the majority overwhelming brain tumors with norm continued existence of one year and presents only one of its kind challenges to therapy because of its violent behavior. Modern treatment approach involves surgery, radiotherapy, immunotherapy, and adjuvant chemotherapy even supposing most favorable management requires a multidisciplinary come up to and knowledge of probable

complications from mutually the disease and its treatment. TQ interferes in a wide range of tumorigenic processes and frustrate carcinogenesis, malignant growth, incursion, exodus, and angiogenesis. (Figure 3).



**Figure no. 3:** Signaling pathways of proliferation in glioblastoma targeted by Thymoquinone

A most important neuroepithelial tumor of the brain, characterized by a belligerent clinical phenotype resultant from inter- and inpatient genomic and histopathological assortment. In the latest reclassification of the World Health Organization (WHO), the GBMs are listed in the group of disseminate astrocytic and oligodendroglial tumors shimmering their exceedingly malignant activities. It constitutes more than 40% of every one malignant brain tumors and in the order of 54.4% all malignant gliomas with mean age at diagnosis being 64 years and 1.5 times more ordinary in men than women. (Figure 4).



**Figure no. 4:** Antiapoptotic and chemosensitization potential of Thymoquinone

In this assessment we summarized the probable role of TQ in dissimilar signaling pathway in GBM that have undergone cure with average therapeutic modalities or with TQ. Overall we suggest further all-inclusive evaluation of TQ in preclinical and clinical level to describe its oblique helpfulness as work of fiction therapeutics to struggle the challenges for the treatment of GBM (Figure 5).




Figure no. 5: Potential beneficiary role of Thymoquinone in mediating different immunotherapeutic modalities

### III. GI Cancers: Colon Cancer

The curative probable of TQ in two dissimilar murine colon cancer models, viz. 1, 2-dimethyl hydrazine (DMH), and xenografts representation. In the DMH representation TQ was injected intra peritoneal and the diversity, dimension, and allocation of aberrant crypt foci (ACF) and tumors were dogged at Weeks 10, 20, and 30. TQ appreciably condensed the numbers and sizes of ACF by 86%, and tumor large quantity at Week 20 was reduced from 17.8 in the DMH group to 4.2 in mice injected with TQ. This outcome persisted, and tumors did not regroup even when TQ injection was discontinued for 10 wk; and immunostaining for capsized 3 cleavages in relic tumors inveterate greater than before apoptosis in retort to TQ.

In the xenograft mock-up of HCT116 colon cancer cells, TQ appreciably ( $P < 0.05$ ) belated the expansion of the tumors with greater than before facts of apoptosis deduced from TUNEL tint of xenografts tumors sustaining the probable use of TQ as a therapeutic agent in human colorectal cancer (18).

### IV. Fore stomach Cancer

Defense to mice aligned with benzo(a)pyrene [B(a)P] induced fore stomach carcinogenesis and chromosomal aberrations (CAs) in bone marrow cells by TQ was reported by Badary (19). From their surveillance it was anecdotal that daily intake of the compound before, after, or during disclosure to B(a)P considerably reduced the frequencies of CAs and dented cells compared to the vastly clastogenic commotion of B(a)P alone. In totting up, tumor occurrence and diversity was seen subdued in as much as 70 and 67%, correspondingly.

### V. Fibrosarcoma

The augmentation inhibitory and antitumor effects of TQ were more premeditated by Badary and Gamal El Din (20) in fibrosarcoma induced by 20-methylcholanthrene (MC) in male Swiss albino mice. TQ was originate effectual not only in drastically inhibiting tumor frequency and tumor burden (34% compared to 100% in control tumor-bearing mice), but it also delayed the onset of MC-induced fibrosarcoma tumors—investigative of chemo preventive exploit against MC-induced fibrosarcomas.

## **VI. Ehrlich Ascites Carcinoma (EAC)**

Badary (21) measured achievable augmentation of the antitumor activity of cisplatin by TQ in Ehrlich ascites carcinoma (EAC)-deportment mice and legitimate that TQ (50 mg/l in drinking water), when given 5 days before and 5 days after single injection of cisplatin, abrogated cisplatin nephrotoxicity and potentiated the antitumor action of cisplatin. One more study reported by Badary (22) in mice department EAC xenograft, renowned that TQ (10 mg/kg/day) in drinking water considerably improved the antitumor effect of Ifosfamide. Mice treated with Ifosfamide in mishmash with TQ showed less body mass loss and mortality rate compared to Ifosfamide monotherapy. These explanations reveal that TQ may get better the therapeutic usefulness of Ifosfamide, cisplatin and in adding together, reverses Ifosfamide- and cisplatin-induced nephrotoxicity by preventing renal GST exhaustion and lipid peroxide production and improving their antitumor efficiency.

## **VII. Prostate Cancer**

Kaseb (23) experiential in a xenograft prostate tumor model that TQ introverted growth of C4–2B plagiaristic tumors in nude mice. This was connected with a spectacular decrease in androgen receptor, transcript factor E2F-1, and cyclin A as resolute by Western blot analysis. Their conclusion clearly put forward that TQ may prove to be an effectual agent in treating hormone sensitive, as well as hormone intractable, prostate cancers with realistic degree of selectivity. TQ was also shown in an additional study of human being prostate cancer (PC3 cells) xenograft to restrain the tumor growth and block angiogenesis with just about no toxic side effects (24).

## **VIII. Conclusion**

Based on the preceding explanation, the therapeutic probable of TQ should not be destabilized even though lack of any study accounting their bioavailability, which needs to be pursued. Once a accord on its bioavailability emerges, intended Phase I clinical trials to authenticate its convenience in chemosensitization and position as chemopreventive agent must be prioritized for dissimilar site-specific cancers. In the intervening time, efforts should keep on focusing on laboratory research to gain further in-depth considerate on its molecular method of accomplishment as well as to devise strategy to invent potent analogs with smallest amount to little side effects, with the decisive goal of translating the profit of this environment endowed compound for therapeutic uses for diseases afflict humans.

## **References**

- [1]. El-Far, A.; Bazh, E.K.; Moharam, M. Antioxidant and antinematodal effects of *Nigella sativa* and *Zingiber officinale* supplementations in ewes. *Int. J. Pharm. Sci. Rev. Res.* 2014, 26, 222–227.
- [2]. El-Far, A.H. Thymoquinone anticancer discovery: Possible mechanisms. *Curr. Drug Discov. Technol.* 2015, 12, 80–89. [CrossRef] [PubMed]
- [3]. El-Far, A.H.; Korshom, M.A.; Mandour, A.A.; El-Bessoumy, A.A.; El-Sayed, Y.S. Hepatoprotective efficacy of *Nigella sativa* seeds dietary supplementation against lead acetate-induced oxidative damage in rabbit—purification and characterization of glutathione peroxidase. *Biomed. Pharmacother.* 2017, 89, 711–718. [CrossRef] [PubMed]
- [4]. Banerjee, S.; Padhye, S.; Azmi, A.; Wang, Z.W.; Philip, P.A.; Kucuk, O.; Sarkar, F.H.; Mohammad, R.M. Review on molecular and therapeutic potential of thymoquinone in cancer. *Nutr. Cancer* 2010, 62, 938–946. [CrossRef] [PubMed]
- [5]. Darakhshan, S.; Pour, A.B.; Colagar, A.H.; Sisakhtnezhad, S. Thymoquinone and its therapeutic potentials. *Pharmacol. Res.* 2015, 95–96, 138–158. [CrossRef] [PubMed]
- [6]. Salmani, J.M.; Asghar, S.; Lv, H.X.; Zhou, J.P. Aqueous solubility and degradation kinetics of the phytochemical anticancer thymoquinone; probing the effects of solvents, pH and light. *Molecules* 2014, 19, 5925–5939. [CrossRef] [PubMed]
- [7]. Alkharfy, K.M.; Ahmad, A.; Khan, R.M.; Al-Shagha, W.M. Pharmacokinetic plasma behaviors of intravenous and oral bioavailability of thymoquinone in a rabbit model. *Eur. J. Drug Metab. Pharmacokinet.* 2015, 40, 319–323. [CrossRef] [PubMed]
- [8]. Schneider-Stock, R.; Fakhoury, I.H.; Zaki, A.M.; El-Baba, C.O.; Gali-Muhtasib, H.U. Thymoquinone: Fifty years of success in the battle against cancer models. *Drug Discov. Today* 2014, 19, 18–30. [CrossRef] [PubMed]
- [9]. Ballout, F.; Habli, Z.; Rahal, O.N.; Fatfat, M.; Gali-Muhtasib, H. Thymoquinone-based nanotechnology for cancer therapy: Promises and challenges. *Drug Discov. Today* 2018, 23, 1089–1098. [CrossRef] [PubMed]
- [10]. Gupta, B.; Ghosh, K.K. Thymoquinone. In *Nutraceuticals: Efficacy, Safety and Toxicity*; Gupta, R.C., Ed.; Elsevier: Boston, MA, USA, 2016; pp. 541–550.
- [11]. Imran, M.; Rauf, A.; Khan, I.A.; Shahbaz, M.; Qaisrani, T.B.; Fatmawati, S.; Abu-Izneid, T.; Imran, A.; Ur Rahman, K.; Gondal, T.A. Thymoquinone: A novel strategy to combat cancer: A review. *Biomed. Pharmacother.* 2018, 106, 390–402. [CrossRef] [PubMed]
- [12]. Khader, M.; Eckl, P.M. Thymoquinone: An emerging natural drug with a wide range of medical applications. *Iran J. Basic Med. Sci.* 2014, 17, 950–957. [PubMed]
- [13]. Srinivas, P.R.; Philbert, M.; Vu, T.Q.; Huang, Q.; Kokini, J.L.; Saltos, E.; Chen, H.; Peterson, C.M.; Friedl, K.E.; McDade-Ngutter, C.; et al. Nanotechnology research: Applications in nutritional sciences. *J. Nutr.* 2010, 140, 119–124. [CrossRef] [PubMed]
- [14]. Li, W.; Yalcin, M.; Lin, Q.; Ardawi, M.M.; Mousa, S.A. Self-assembly of green tea catechin derivatives in nanoparticles for oral lycopene delivery. *J. Control. Release* 2017, 248, 117–124. [CrossRef] [PubMed]
- [15]. Weiss, J.; Takhistov, P.; McClements, D.J. Functional materials in food nanotechnology. *J. Food Sci.* 2006, 71, R107–R116. [CrossRef]

- [16]. Nihei, T.; Suzuki, H.; Aoki, A.; Yuminoki, K.; Hashimoto, N.; Sato, H.; Seto, Y.; Onoue, S. Development of a novel nanoparticle formulation of thymoquinone with a cold wet-milling system and its pharmacokinetic analysis. *Int. J. Pharm.* 2016, 511, 455–461. [CrossRef] [PubMed]
- [17]. Zamboni, W.C. Concept and clinical evaluation of carrier-mediated anticancer agents. *Oncologist* 2008, 13, 248–260. [CrossRef] [PubMed]
- [18]. Gali-Muhtasib H, Ocker M, Kuester D, Krueger S, El-Hajj Z, et al. Thymoquinone reduces mouse colon tumor cell invasion and inhibits tumor growth in murine colon cancer models. *J Cell Mol Med.* 2008;12:330–342. [PMC free article] [PubMed] [Google Scholar]
- [19]. Badary OA, Al-Shabanah OA, Nagi MN, Al-Rikabi AC, Elmazar MM. Inhibition of benzo(a)pyrene-induced forestomach carcinogenesis in mice by thymoquinone. *Eur J Cancer Prev.* 1999;8:435–440. [PubMed] [Google Scholar]
- [20]. Badary OA, Gamal El-Din AM. Inhibitory effects of thymoquinone against 20-methylcholanthrene-induced fibrosarcoma tumorigenesis. *Cancer Detect Prev.* 2001;25:362–368. [PubMed] [Google Scholar]
- [21]. Badary OA, Nagi MN, al-Shabanah OA, al-Sawaf HA, al-Sohaibani MO, et al. Thymoquinone ameliorates the nephrotoxicity induced by cisplatin in rodents and potentiates its antitumor activity. *Can J Physiol Pharmacol.* 1997;75:1356–1361. [PubMed] [Google Scholar]
- [22]. Badary OA. Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice. *J Ethnopharmacol.* 1999;67:135–142
- [23]. Kaseb AO, Chinnakannu K, Chen D, Sivanandam A, Tejawari S, et al. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. *Cancer Res.* 2007;67:7782–7788. [PubMed] [Google Scholar]
- [24]. Chehl N, Chipitsyna G, Gong Q, Yeo CJ, Arafat HA. Anti-inflammatory effects of the *Nigella sativa* seed extract, thymoquinone, in pancreatic cancer cells. *HPB (Oxford)* 2009;11:373–381. [PMC free article] [PubMed] [Google Scholar]